William Stringer
Pulmonary Disease · Torrance, CANPI 1487633111
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,090 of the $26,216 with a category attached, or 80.4%. 17 manufacturers reported payments, led by Regeneron at 32.4% of the total. Reporting peaked in 2023 at $13,058 and has fallen 73.9% since, to $3,406 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $416.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$9K
- GSK$5K
- Genentech, Inc.$5K
- Astrazeneca UK Limited$2K
- Vyaire Medical, Inc.$2K
- Verona Pharma, Inc.$2K
- plus $2K from 11 others
Across 127 payments — averaging $8170.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$233K
- AstraZeneca$230K
- Astrazeneca UK Limited$216K
- Boehringer Ingelheim$182K
- Prolaio, Inc.$74K
- Regeneron$35K
- plus $67K from 7 others
What the payments were for
- Consulting fees$21,09080%
- Travel & lodging$3,64014%
- Food & beverage$1,4866%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 24 | $8,500 |
| GSK | 6 | $5,201 |
| Genentech, Inc. | 5 | $4,519 |
| Astrazeneca UK Limited | 9 | $2,104 |
| Vyaire Medical, Inc. | 1 | $2,100 |
| Verona Pharma, Inc. | 1 | $1,800 |
| Prolaio, Inc. | 2 | $1,500 |
| Merck | 6 | $129 |
| Boehringer Ingelheim | 1 | $125 |
| Medical Graphics Corporation | 1 | $64 |
| AstraZeneca | 1 | $39 |
| Medivance, Inc. | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
| Pfizer | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$8,500
- TRELEGY ELLIPTA$5,015
- BREZTRI$2,038
- Ohtuvayre$1,800
- OFEV$125
How this compares
$26,216 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Torrance
- Catherine ObergTorrance$457K
- Richard CasaburiTorrance$208K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.